#HCPs At this year’s #ENDO2024, #AscendisPharma will share results from the Phase 3 foresiGHt clinical trial in adult #growthhormonedeficiency on June 3.
Ascendis Pharma
Forskning inden for bioteknologi
Hellerup, Capital Region of Denmark 49.995 følgere
Committed to making a meaningful difference for patients
Om os
Ascendis Pharma is applying our innovative TransCon technology platform to build a leading, fully integrated biopharmaceutical company focused on making a meaningful difference in patients’ lives. Guided by our core values of patients, science and passion, we utilize our TransCon technology platform to create new and potentially best-in-class therapies. Ascendis Pharma currently has three independent endocrinology rare disease product candidates in clinical development and we're also advancing programs in Oncology and Ophthalmology. Ascendis Pharma is headquartered in Copenhagen, Denmark, with additional offices in Heidelberg, Munich, and Berlin, Germany, Palo Alto and Redwood City, California, and Princeton, New Jersey.
- Websted
-
http://www.ascendispharma.com
Eksternt link til Ascendis Pharma
- Branche
- Forskning inden for bioteknologi
- Virksomhedsstørrelse
- 501 – 1.000 medarbejdere
- Hovedkvarter
- Hellerup, Capital Region of Denmark
- Type
- Aktieselskab
- Grundlagt
- 2007
- Specialer
- Endocrinology, Oncology, Drug Development, Innovation, Globalization , Ophthalmology og TransCon Technology
Beliggenheder
-
Primær
Se ruten
Tuborg Boulevard 12
Hellerup, Capital Region of Denmark 2900, DK
Medarbejdere hos Ascendis Pharma
Opdateringer
-
We are proud to partner with organizations like the HypoPARAthyroidism Association who strive to make a difference in patients’ lives by driving #hypoPARA community support, education, stories, and resources. #raredisease #hypoparathyroidism
-
-
#AscendisPharma is so excited to have spent this #WorldHypoparaDay in-person with #endocrinology experts and advocacy groups at #ENDO2024.
-
-
#Hypoparathyroidism is a rare endocrine disease resulting from the absence or deficiency of parathyroid hormone (PTH) in the body and can be linked to several multiorgan manifestations, including cardiovascular, respiratory, and renal complications. To learn more about this #raredisease, check out this journal article: https://lnkd.in/eiN-9SAX
-
-
#AscendisPharma honors #WorldHypoparaDay and those impacted by this under-recognized #raredisease.
-
-
#HCPs Join #AscendisPharma at our symposium on pediatric #growthhormonedeficiency – taking place June 2 at #ENDO2024 in Boston.
-
-
#HCPs #AscendisPharma is heading to Boston for #ENDO2024 from June 1-4. Come visit us at booth 1001 – we look forward to seeing you there!
-
-
#HCPs #AscendisPharma to share IL-2 β⁄γ immunotherapy results from our Phase 1/2 IL-Believe trial at #ASCO24, the American Society of Clinical Oncology Annual Meeting in Chicago on June 1.
-
-
#HCPs This week is the 2024 American Society of Clinical Oncology Annual Meeting and #AscendisPharma is looking forward to being on-site in Chicago. Come visit us at booth 36165 to learn more about our work in #immunotherapy. #ASCO24
-
-
This #InternationalWomensHealthDay, #AscendisPharma recognizes women living with #rare endocrine diseases and those who are tirelessly working to improve the health and well-being of women around the world.
-
Tilsvarende sider
Finansiering
Ascendis Pharma
6 runder i alt
![]()
Royalty Pharma
Læs mere på crunchbase
Seneste runde
Post IPO-gæld
Eksternt Crunchbase-link til seneste finansieringsrunde
150.000.000,00 US$
Investorer